4Tissue
ActiveSummary
The annual accounts of 4Tissue for financial year 2025 show a net loss of 127% of the equity at the start of that year. The 2025 annual accounts show equity of €845,476 and a net result of -€727,036. Equity is growing by about 74% per year across the filed financial years. Its solvency ranks better than 43% of 780 sector peers (NACE 32, financial year 2025). The company has been active since 2023 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.5% (low).
Directors
Board 6
Day-to-day management 4
Permanent representatives 5
Not every act has been read: a resignation may still be missing
Mandate history
- Board
- Day-to-day management
| Name | Functions and periods |
|---|---|
| BLONDEEL Phillip |
|
| DEPYPERE Bernard |
|
| LAWOTI |
|
| VAN DE CASTEELE Anne |
|
| VAN VLIERBERGHE Sandra |
|
| SAS KBK |
|
| ROBIUM |
|
| BENOIT MOREAUX |
|
| VAN DAMME Lana |
|
| MARACUJAS |
|
| An VAN DEN BULCKE |
|
Owners and capital
Capital and shareholders
- VAN DEN BULCKE An 3,000 shares (20%)
- BLONDEEL Philip 3,000 shares (20%)
- VAN DAMME Lana 3,000 shares (20%)
- DEPYPERE Bernard 3,000 shares (20%)
- VAN VLIERBERGHE Sandra 3,000 shares (20%)
The Belgian Official Gazette names shareholders only when an act mentions them; the share register itself is not published.
- 25-02-2025 Capital increase of €999,800 · 4,999 new shares · in cash
- 03-05-2024 Capital increase of €900,000 · 4,500 new shares · in cash
- 21-03-2023 Incorporation · €15,000 · 15,000 shares